Matinas Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $30.32 million. The Firm is engaged in the development of targeted therapeutics using its lipid drug delivery platform and the development of lipid prescription therapeutics for the treatment of cardiovascular and metabolic conditions. It currently has negative earnings. The Company’s cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation.

The post Earnings Per Share Preview for Matinas BioPharma Holdings Inc (MTNB) appeared first on Octafinance.